Celadon is focused on putting the patient first
In March 2022, we achieved the huge milestone of our AIM listing on the London Stock Exchange. Since then we have been highly focused on delivering the plan we set out. For Celadon, the patient comes first. I frequently talk to patients who have used cannabis-based products for chronic pain, and other conditions; I know how life-changing this can be for patients who are most in need in society. Celadon is excited to be at the forefront of the sector and has huge ambitions to take the business forward. I would like to personally welcome our new investors and thank them, and the original investors, for their trust in me and our incredible team.
JAMES SHORT CEO & Co-Founder of Celadon Pharmaceuticals Plc
Patient-first approach, supported by Celadon’s integrated R&D, clinical trials
and licenced supply chain; ability to get to early revenue through UK "Specials" framework.
ROBUST INVESTMENT CASE
First mover advantage and high regulatory and operational barriers to entry
One of the first companies licenced by UK regulators, with MHRA (conditional) approval for clinical trial using CBMPs.
Global market for cannabis-based medicines forecast to grow at ~27% CAGR to US$53bn by 2027, with significant chronic pain patient pools (e.g. 50 million in U.S.).
Deep domain expertise across pharmaceuticals, R&D, Quality and agronomy.
Attractive unit economics
High margin pharmaceutical-grade products and scalable business model with significant free cash flow potential.
Positioned for growth
UK-based platform benefiting from demand for pharmaceutical-grade CBMPs and clinical trials, augmented by strategic partnership and M&A opportunities.
FIND OUT MORE